What is HC Wainwright's Forecast for LENZ Q2 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.60) per share for the quarter. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $1.45 EPS.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Several other research firms have also recently weighed in on LENZ. Citigroup upped their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. TD Cowen started coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $41.67.

Remove Ads

LENZ Therapeutics Stock Performance

NASDAQ LENZ traded up $0.44 during trading hours on Monday, reaching $26.53. 88,675 shares of the company's stock were exchanged, compared to its average volume of 166,747. The company has a market capitalization of $730.72 million, a price-to-earnings ratio of -5.56 and a beta of 0.58. The company's 50-day moving average is $24.37 and its two-hundred day moving average is $27.11. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93.

Institutional Trading of LENZ Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics during the fourth quarter worth $29,000. KLP Kapitalforvaltning AS bought a new stake in LENZ Therapeutics during the 4th quarter worth about $46,000. Tower Research Capital LLC TRC boosted its stake in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after buying an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of LENZ Therapeutics in the 4th quarter valued at about $67,000. Finally, SG Americas Securities LLC grew its holdings in shares of LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock valued at $158,000 after acquiring an additional 935 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.